Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

Platelet-Derived Growth Factor-D Enables Liver Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma.

Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L.

J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32620-5. doi: 10.1016/j.jhep.2018.12.004. [Epub ahead of print]

PMID:
30553841
2.

Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies.

Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M.

Int J Mol Sci. 2018 Dec 4;19(12). pii: E3875. doi: 10.3390/ijms19123875. Review.

3.

Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S.

J Comput Assist Tomogr. 2018 Nov 6. doi: 10.1097/RCT.0000000000000807. [Epub ahead of print]

PMID:
30407241
4.

Animal models of cholestasis: An update on inflammatory cholangiopathies.

Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L.

Biochim Biophys Acta Mol Basis Dis. 2018 Aug 11. pii: S0925-4439(18)30274-6. doi: 10.1016/j.bbadis.2018.07.025. [Epub ahead of print] Review.

PMID:
30398152
5.

Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation.

Riva G, Cilibrasi C, Bazzoni R, Cadamuro M, Negroni C, Butta V, Strazzabosco M, Dalprà L, Lavitrano M, Bentivegna A.

Genes (Basel). 2018 Oct 26;9(11). pii: E522. doi: 10.3390/genes9110522.

6.

Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M.

Biochim Biophys Acta Mol Basis Dis. 2018 Sep 5. pii: S0925-4439(18)30331-4. doi: 10.1016/j.bbadis.2018.08.038. [Epub ahead of print] Review.

PMID:
30264693
7.

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang XW, Zhu AX.

Hepatology. 2018 Sep 25. doi: 10.1002/hep.30289. [Epub ahead of print]

PMID:
30251463
8.

Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.

Ippolito D, Querques G, Okolicsanyi S, Talei Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S.

Eur J Radiol. 2018 Sep;106:62-68. doi: 10.1016/j.ejrad.2018.07.012. Epub 2018 Jul 20.

PMID:
30150052
9.

Animal models for cystic fibrosis liver disease (CFLD).

Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M.

Biochim Biophys Acta Mol Basis Dis. 2018 Jul 30. pii: S0925-4439(18)30275-8. doi: 10.1016/j.bbadis.2018.07.026. [Epub ahead of print] Review.

PMID:
30071276
10.

Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.

Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Moreno Gonzales E, Charco R, Zieniewicz K, De Carlis L, Duvoux C; all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA).

J Hepatol. 2018 Oct;69(4):810-817. doi: 10.1016/j.jhep.2018.06.010. Epub 2018 Jun 27.

PMID:
29940268
11.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10.

12.

Animal models of cholangiocarcinoma: What they teach us about the human disease.

Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):403-415. doi: 10.1016/j.clinre.2018.04.008. Epub 2018 May 9. Review.

PMID:
29753731
13.

The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.

Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M; European Liver and Intestine Transplant Association (ELITA).

J Viral Hepat. 2018 Jul;25(7):791-801. doi: 10.1111/jvh.12877. Epub 2018 Mar 8.

PMID:
29406608
14.

Notch signaling and progenitor/ductular reaction in steatohepatitis.

Morell CM, Fiorotto R, Meroni M, Raizner A, Torsello B, Cadamuro M, Spagnuolo G, Kaffe E, Sutti S, Albano E, Strazzabosco M.

PLoS One. 2017 Nov 15;12(11):e0187384. doi: 10.1371/journal.pone.0187384. eCollection 2017.

15.

β-Catenin and interleukin-1β-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis.

Kaffe E, Fiorotto R, Pellegrino F, Mariotti V, Amenduni M, Cadamuro M, Fabris L, Strazzabosco M, Spirli C.

Hepatology. 2018 May;67(5):1903-1919. doi: 10.1002/hep.29652. Epub 2018 Mar 25.

PMID:
29140564
16.

Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Brivio S, Cadamuro M, Fabris L, Strazzabosco M.

Gene Expr. 2018 Mar 21;18(1):31-50. doi: 10.3727/105221617X15088670121925. Epub 2017 Oct 25.

17.

Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine.

Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1415-1422. doi: 10.1016/j.bbadis.2017.08.025. Epub 2017 Aug 24.

PMID:
28844954
18.

Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.

Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M.

Hepatology. 2018 Mar;67(3):972-988. doi: 10.1002/hep.29400. Epub 2018 Jan 26.

PMID:
28836688
19.

The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.

Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1435-1443. doi: 10.1016/j.bbadis.2017.07.028. Epub 2017 Jul 27. Review.

PMID:
28757170
20.

Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.

Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E, Scirpo R, Fabris L.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1374-1379. doi: 10.1016/j.bbadis.2017.07.023. Epub 2017 Jul 25. Review.

PMID:
28754453

Supplemental Content

Loading ...
Support Center